✦ LIBER ✦

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

✍ Scribed by Krop, Ian E; Kim, Sung-Bae; González-Martín, Antonio; LoRusso, Patricia M; Ferrero, Jean-Marc; Smitt, Melanie; Yu, Ron; Leung, Abraham C F; Wildiers, Hans

Book ID: 122183443
Publisher: The Lancet
Year: 2014
Tongue: English
Weight: 422 KB
Volume: 15
Category: Article
ISSN: 1470-2045
DOI: 10.1016/S1470-2045(14)70178-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Trastuzumab emtansine versus treatment o

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

✍ Krop, Ian E; Kim, Sung-Bae; González-Martín, Antonio; LoRusso, Patricia M; Ferre 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 422 KB

## Background: Patients with progressive disease after two or more her2-directed regimens for recurrent or metastatic breast cancer have few effective therapeutic options. we aimed to compare trastuzumab emtansine, an antibody-drug conjugate comprising the cytotoxic agent dm1 linked to trastuzumab,

Lapatinib with trastuzumab for HER2-posi

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

✍ José Baselga; Ian Bradbury; Holger Eidtmann; Serena Di Cosimo; Evandro de Azambu 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 320 KB

2 years versus 1 year of adjuvant trastu

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

✍ Goldhirsch, Aron; Gelber, Richard D; Piccart-Gebhart, Martine J; de Azambuja, Ev 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 449 KB

Trastuzumab in combination with chemothe

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

✍ Yung-Jue Bang; Eric Van Cutsem; Andrea Feyereislova; Hyun C Chung; Lin Shen; Aki 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 332 KB

Eribulin monotherapy versus treatment of

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

✍ Javier Cortes; Joyce O'Shaughnessy; David Loesch; Joanne L Blum; Linda T Vahdat; 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 392 KB

6 months versus 12 months of adjuvant tr

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial

✍ Pivot, Xavier; Romieu, Gilles; Debled, Marc; Pierga, Jean-Yves; Kerbrat, Pierre; 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 358 KB